Pfizer CEO Albert Bourla comments on 2023 pipeline and Covid-19 products.

Video Transcript

ALBERT BOURLA: As previously discussed, in 2023 and 2024, we expect vaccine utilization to decline compared with 2022. Then starting in 2025 and continuing in 2026 and beyond, we expect to see an increase in COVID-19 vaccination rates, assuming the successful development and approval of various COVID combination vaccines.